SARS Virus
9
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (9)
Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19
Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection
Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19
IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.
Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19
Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome
Investigating Severe Acute Respiratory Syndrome (SARS)